Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isoniazid + rifampin + pyrazinamide + ethambutol + levofloxacin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination of five antituberculosis drugs used for the treatment of tuberculosis, particularly in cases where there is resistance to isoniazid or other first-line agents. The regimen typically includes an intensive phase with all five drugs, followed by a continuation phase with fewer agents depending on susceptibility results and clinical response. The combination targets Mycobacterium tuberculosis through multiple mechanisms to prevent resistance and improve efficacy[2][8][6].
- Other names
- isoniazid/rifampicin/pyrazinamide/ethambutol/levofloxacinisoniazid+rifampicin+pyrazinamide+ethambutol+levofloxacin
02
Targets
Aspartate decarboxylaserpoB (DNA-directed RNA polymerase subunit beta)FabI (Enoyl-acyl carrier protein reductase FabI)
Beyond the preview
Go deeper on isoniazid + rifampin + pyrazinamide + ethambutol + levofloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isoniazid + rifampin + pyrazinamide + ethambutol + levofloxacin.